Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite
Background and Purpose Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF). Exp...
Gespeichert in:
Veröffentlicht in: | British journal of pharmacology 2013-06, Vol.169 (3), p.659-670 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 670 |
---|---|
container_issue | 3 |
container_start_page | 659 |
container_title | British journal of pharmacology |
container_volume | 169 |
creator | Maher, Abdul R Arif, Sayqa Madhani, Melanie Abozguia, Khalid Ahmed, Ibrar Fernandez, Bernadette O Feelisch, Martin O'Sullivan, AG Christopoulos, Arthur Sverdlov, Aaron L Ngo, Doan Dautov, Rustem James, Philip E Horowitz, John D Frenneaux, Michael P |
description | Background and Purpose
Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF).
Experimental Approach
The acute haemodynamic effects of brachial artery infusion of NO2− (0.31 to 7.8 μmol·min−1) was assessed in normal subjects (n = 20) and CHF patients (n = 21).
Key Results
NO2− infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2− infusion rates which induced no changes in normal subjects (anova: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2− infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (anova: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2− infusion. Venous plasma NO2− concentrations were lower in CHF patients at baseline, and rose substantially less with NO2− infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2− infusion. Prolonged NO2− exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro.
Conclusions and Implications
The findings of arterial hyper‐responsiveness to infused NO2− in CHF patients, with evidence of accelerated transvascular NO2− clearance (presumably with concomitant NO release) suggests that NO2− effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2− as a therapeutic modality in CHF. |
doi_str_mv | 10.1111/bph.12152 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3682712</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3316012971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4762-15ec056cc388b3837003ca71b5d15c4d8c5cbf01ed2cb294a03905170d5b403b3</originalsourceid><addsrcrecordid>eNp1kc1u1DAUhS1ERYfCghdAltjAIq1_4rFngwQV_ZEqtQtYW87NzcQlsYOdDOrb4zKlokh448X99PlcH0LecHbMyzlppv6YC67EM7LitV5XShr-nKwYY7ri3JhD8jLnW8bKUKsX5FDIWgujNyuyvRwnBzONHYU-xeCBQgxbzLPfIe3RpZl2zg9LQhoDnXqXRgfxuw84e8jUhZbuXI5jnGOi2HUIc763-dAtGVsa_Jz8jK_IQeeGjK8f7iPy7ezL19OL6ur6_PL001UFJbeouEJgag0gjWmkkZoxCU7zRrVcQd0aUNB0jGMroBGb2jG5YYpr1qqmZrKRR-Tj3jstzYgtYJiTG-yU_OjSnY3O26eT4Hu7jTsr10ZoLorg_YMgxR9L-Qc7-gw4DC5gXLLlJVR5WEtW0Hf_oLdxSaGsZ0sXZi3qut4U6sOeghRzTtg9huHM3tdnS332d32Ffft3-kfyT18FONkDP_2Ad_832c83F3vlL8EqpbU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1528624449</pqid></control><display><type>article</type><title>Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Maher, Abdul R ; Arif, Sayqa ; Madhani, Melanie ; Abozguia, Khalid ; Ahmed, Ibrar ; Fernandez, Bernadette O ; Feelisch, Martin ; O'Sullivan, AG ; Christopoulos, Arthur ; Sverdlov, Aaron L ; Ngo, Doan ; Dautov, Rustem ; James, Philip E ; Horowitz, John D ; Frenneaux, Michael P</creator><creatorcontrib>Maher, Abdul R ; Arif, Sayqa ; Madhani, Melanie ; Abozguia, Khalid ; Ahmed, Ibrar ; Fernandez, Bernadette O ; Feelisch, Martin ; O'Sullivan, AG ; Christopoulos, Arthur ; Sverdlov, Aaron L ; Ngo, Doan ; Dautov, Rustem ; James, Philip E ; Horowitz, John D ; Frenneaux, Michael P</creatorcontrib><description>Background and Purpose
Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF).
Experimental Approach
The acute haemodynamic effects of brachial artery infusion of NO2− (0.31 to 7.8 μmol·min−1) was assessed in normal subjects (n = 20) and CHF patients (n = 21).
Key Results
NO2− infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2− infusion rates which induced no changes in normal subjects (anova: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2− infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (anova: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2− infusion. Venous plasma NO2− concentrations were lower in CHF patients at baseline, and rose substantially less with NO2− infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2− infusion. Prolonged NO2− exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro.
Conclusions and Implications
The findings of arterial hyper‐responsiveness to infused NO2− in CHF patients, with evidence of accelerated transvascular NO2− clearance (presumably with concomitant NO release) suggests that NO2− effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2− as a therapeutic modality in CHF.</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.12152</identifier><identifier>PMID: 23472879</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Aged ; Brachial Artery ; Cohort Studies ; Drug Tolerance ; Female ; Forearm ; heart failure ; Heart Failure - drug therapy ; Heart Failure - metabolism ; Heart Failure - physiopathology ; Hemodynamics - drug effects ; Humans ; In Vitro Techniques ; Infusions, Intra-Arterial ; Male ; Metabolic Clearance Rate ; Middle Aged ; Nitric Oxide - administration & dosage ; Nitric Oxide - analogs & derivatives ; Nitric Oxide - metabolism ; Nitric Oxide - pharmacokinetics ; Nitroglycerin - administration & dosage ; Nitroglycerin - metabolism ; Nitroglycerin - pharmacokinetics ; Nitroglycerin - pharmacology ; Oxidative Stress - drug effects ; Regional Blood Flow - drug effects ; Research Papers ; Saphenous Vein - drug effects ; Saphenous Vein - physiopathology ; sodium nitrite ; Sodium Nitrite - administration & dosage ; Sodium Nitrite - metabolism ; Sodium Nitrite - pharmacokinetics ; Sodium Nitrite - pharmacology ; vascular effects ; Vasodilation - drug effects ; Vasodilator Agents - administration & dosage ; Vasodilator Agents - metabolism ; Vasodilator Agents - pharmacokinetics ; Vasodilator Agents - pharmacology ; Vasomotor System - drug effects ; Vasomotor System - physiopathology</subject><ispartof>British journal of pharmacology, 2013-06, Vol.169 (3), p.659-670</ispartof><rights>2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society</rights><rights>2013 The Authors. British Journal of Pharmacology © 2013 The British Pharmacological Society.</rights><rights>British Journal of Pharmacology © 2013 The British Pharmacological Society</rights><rights>British Journal of Pharmacology © 2013 The British Pharmacological Society 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4762-15ec056cc388b3837003ca71b5d15c4d8c5cbf01ed2cb294a03905170d5b403b3</citedby><cites>FETCH-LOGICAL-c4762-15ec056cc388b3837003ca71b5d15c4d8c5cbf01ed2cb294a03905170d5b403b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682712/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682712/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23472879$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maher, Abdul R</creatorcontrib><creatorcontrib>Arif, Sayqa</creatorcontrib><creatorcontrib>Madhani, Melanie</creatorcontrib><creatorcontrib>Abozguia, Khalid</creatorcontrib><creatorcontrib>Ahmed, Ibrar</creatorcontrib><creatorcontrib>Fernandez, Bernadette O</creatorcontrib><creatorcontrib>Feelisch, Martin</creatorcontrib><creatorcontrib>O'Sullivan, AG</creatorcontrib><creatorcontrib>Christopoulos, Arthur</creatorcontrib><creatorcontrib>Sverdlov, Aaron L</creatorcontrib><creatorcontrib>Ngo, Doan</creatorcontrib><creatorcontrib>Dautov, Rustem</creatorcontrib><creatorcontrib>James, Philip E</creatorcontrib><creatorcontrib>Horowitz, John D</creatorcontrib><creatorcontrib>Frenneaux, Michael P</creatorcontrib><title>Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Background and Purpose
Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF).
Experimental Approach
The acute haemodynamic effects of brachial artery infusion of NO2− (0.31 to 7.8 μmol·min−1) was assessed in normal subjects (n = 20) and CHF patients (n = 21).
Key Results
NO2− infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2− infusion rates which induced no changes in normal subjects (anova: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2− infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (anova: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2− infusion. Venous plasma NO2− concentrations were lower in CHF patients at baseline, and rose substantially less with NO2− infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2− infusion. Prolonged NO2− exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro.
Conclusions and Implications
The findings of arterial hyper‐responsiveness to infused NO2− in CHF patients, with evidence of accelerated transvascular NO2− clearance (presumably with concomitant NO release) suggests that NO2− effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2− as a therapeutic modality in CHF.</description><subject>Aged</subject><subject>Brachial Artery</subject><subject>Cohort Studies</subject><subject>Drug Tolerance</subject><subject>Female</subject><subject>Forearm</subject><subject>heart failure</subject><subject>Heart Failure - drug therapy</subject><subject>Heart Failure - metabolism</subject><subject>Heart Failure - physiopathology</subject><subject>Hemodynamics - drug effects</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Infusions, Intra-Arterial</subject><subject>Male</subject><subject>Metabolic Clearance Rate</subject><subject>Middle Aged</subject><subject>Nitric Oxide - administration & dosage</subject><subject>Nitric Oxide - analogs & derivatives</subject><subject>Nitric Oxide - metabolism</subject><subject>Nitric Oxide - pharmacokinetics</subject><subject>Nitroglycerin - administration & dosage</subject><subject>Nitroglycerin - metabolism</subject><subject>Nitroglycerin - pharmacokinetics</subject><subject>Nitroglycerin - pharmacology</subject><subject>Oxidative Stress - drug effects</subject><subject>Regional Blood Flow - drug effects</subject><subject>Research Papers</subject><subject>Saphenous Vein - drug effects</subject><subject>Saphenous Vein - physiopathology</subject><subject>sodium nitrite</subject><subject>Sodium Nitrite - administration & dosage</subject><subject>Sodium Nitrite - metabolism</subject><subject>Sodium Nitrite - pharmacokinetics</subject><subject>Sodium Nitrite - pharmacology</subject><subject>vascular effects</subject><subject>Vasodilation - drug effects</subject><subject>Vasodilator Agents - administration & dosage</subject><subject>Vasodilator Agents - metabolism</subject><subject>Vasodilator Agents - pharmacokinetics</subject><subject>Vasodilator Agents - pharmacology</subject><subject>Vasomotor System - drug effects</subject><subject>Vasomotor System - physiopathology</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc1u1DAUhS1ERYfCghdAltjAIq1_4rFngwQV_ZEqtQtYW87NzcQlsYOdDOrb4zKlokh448X99PlcH0LecHbMyzlppv6YC67EM7LitV5XShr-nKwYY7ri3JhD8jLnW8bKUKsX5FDIWgujNyuyvRwnBzONHYU-xeCBQgxbzLPfIe3RpZl2zg9LQhoDnXqXRgfxuw84e8jUhZbuXI5jnGOi2HUIc763-dAtGVsa_Jz8jK_IQeeGjK8f7iPy7ezL19OL6ur6_PL001UFJbeouEJgag0gjWmkkZoxCU7zRrVcQd0aUNB0jGMroBGb2jG5YYpr1qqmZrKRR-Tj3jstzYgtYJiTG-yU_OjSnY3O26eT4Hu7jTsr10ZoLorg_YMgxR9L-Qc7-gw4DC5gXLLlJVR5WEtW0Hf_oLdxSaGsZ0sXZi3qut4U6sOeghRzTtg9huHM3tdnS332d32Ffft3-kfyT18FONkDP_2Ad_832c83F3vlL8EqpbU</recordid><startdate>201306</startdate><enddate>201306</enddate><creator>Maher, Abdul R</creator><creator>Arif, Sayqa</creator><creator>Madhani, Melanie</creator><creator>Abozguia, Khalid</creator><creator>Ahmed, Ibrar</creator><creator>Fernandez, Bernadette O</creator><creator>Feelisch, Martin</creator><creator>O'Sullivan, AG</creator><creator>Christopoulos, Arthur</creator><creator>Sverdlov, Aaron L</creator><creator>Ngo, Doan</creator><creator>Dautov, Rustem</creator><creator>James, Philip E</creator><creator>Horowitz, John D</creator><creator>Frenneaux, Michael P</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U7</scope><scope>C1K</scope><scope>5PM</scope></search><sort><creationdate>201306</creationdate><title>Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite</title><author>Maher, Abdul R ; Arif, Sayqa ; Madhani, Melanie ; Abozguia, Khalid ; Ahmed, Ibrar ; Fernandez, Bernadette O ; Feelisch, Martin ; O'Sullivan, AG ; Christopoulos, Arthur ; Sverdlov, Aaron L ; Ngo, Doan ; Dautov, Rustem ; James, Philip E ; Horowitz, John D ; Frenneaux, Michael P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4762-15ec056cc388b3837003ca71b5d15c4d8c5cbf01ed2cb294a03905170d5b403b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Brachial Artery</topic><topic>Cohort Studies</topic><topic>Drug Tolerance</topic><topic>Female</topic><topic>Forearm</topic><topic>heart failure</topic><topic>Heart Failure - drug therapy</topic><topic>Heart Failure - metabolism</topic><topic>Heart Failure - physiopathology</topic><topic>Hemodynamics - drug effects</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Infusions, Intra-Arterial</topic><topic>Male</topic><topic>Metabolic Clearance Rate</topic><topic>Middle Aged</topic><topic>Nitric Oxide - administration & dosage</topic><topic>Nitric Oxide - analogs & derivatives</topic><topic>Nitric Oxide - metabolism</topic><topic>Nitric Oxide - pharmacokinetics</topic><topic>Nitroglycerin - administration & dosage</topic><topic>Nitroglycerin - metabolism</topic><topic>Nitroglycerin - pharmacokinetics</topic><topic>Nitroglycerin - pharmacology</topic><topic>Oxidative Stress - drug effects</topic><topic>Regional Blood Flow - drug effects</topic><topic>Research Papers</topic><topic>Saphenous Vein - drug effects</topic><topic>Saphenous Vein - physiopathology</topic><topic>sodium nitrite</topic><topic>Sodium Nitrite - administration & dosage</topic><topic>Sodium Nitrite - metabolism</topic><topic>Sodium Nitrite - pharmacokinetics</topic><topic>Sodium Nitrite - pharmacology</topic><topic>vascular effects</topic><topic>Vasodilation - drug effects</topic><topic>Vasodilator Agents - administration & dosage</topic><topic>Vasodilator Agents - metabolism</topic><topic>Vasodilator Agents - pharmacokinetics</topic><topic>Vasodilator Agents - pharmacology</topic><topic>Vasomotor System - drug effects</topic><topic>Vasomotor System - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maher, Abdul R</creatorcontrib><creatorcontrib>Arif, Sayqa</creatorcontrib><creatorcontrib>Madhani, Melanie</creatorcontrib><creatorcontrib>Abozguia, Khalid</creatorcontrib><creatorcontrib>Ahmed, Ibrar</creatorcontrib><creatorcontrib>Fernandez, Bernadette O</creatorcontrib><creatorcontrib>Feelisch, Martin</creatorcontrib><creatorcontrib>O'Sullivan, AG</creatorcontrib><creatorcontrib>Christopoulos, Arthur</creatorcontrib><creatorcontrib>Sverdlov, Aaron L</creatorcontrib><creatorcontrib>Ngo, Doan</creatorcontrib><creatorcontrib>Dautov, Rustem</creatorcontrib><creatorcontrib>James, Philip E</creatorcontrib><creatorcontrib>Horowitz, John D</creatorcontrib><creatorcontrib>Frenneaux, Michael P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maher, Abdul R</au><au>Arif, Sayqa</au><au>Madhani, Melanie</au><au>Abozguia, Khalid</au><au>Ahmed, Ibrar</au><au>Fernandez, Bernadette O</au><au>Feelisch, Martin</au><au>O'Sullivan, AG</au><au>Christopoulos, Arthur</au><au>Sverdlov, Aaron L</au><au>Ngo, Doan</au><au>Dautov, Rustem</au><au>James, Philip E</au><au>Horowitz, John D</au><au>Frenneaux, Michael P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2013-06</date><risdate>2013</risdate><volume>169</volume><issue>3</issue><spage>659</spage><epage>670</epage><pages>659-670</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Background and Purpose
Nitrite (NO2−) has recently been shown to represent a potential source of NO, in particular under hypoxic conditions. The aim of the current study was to compare the haemodynamic effects of NO2− in healthy volunteers and patients with stable congestive heart failure (CHF).
Experimental Approach
The acute haemodynamic effects of brachial artery infusion of NO2− (0.31 to 7.8 μmol·min−1) was assessed in normal subjects (n = 20) and CHF patients (n = 21).
Key Results
NO2− infusion was well tolerated in all subjects. Forearm blood flow (FBF) increased markedly in CHF patients at NO2− infusion rates which induced no changes in normal subjects (anova: F = 5.5; P = 0.02). Unstressed venous volume (UVV) increased even with the lowest NO2− infusion rate in all subjects (indicating venodilation), with CHF patients being relatively hyporesponsive compared with normal subjects (anova: F = 6.2; P = 0.01). There were no differences in venous blood pH or oxygen concentration between groups or during NO2− infusion. Venous plasma NO2− concentrations were lower in CHF patients at baseline, and rose substantially less with NO2− infusion, without incremental oxidative generation of nitrate, consistent with accelerated clearance in these patients. Plasma protein‐bound NO concentrations were lower in CHF patients than normal subjects at baseline. This difference was attenuated during NO2− infusion. Prolonged NO2− exposure in vivo did not induce oxidative stress, nor did it induce tolerance in vitro.
Conclusions and Implications
The findings of arterial hyper‐responsiveness to infused NO2− in CHF patients, with evidence of accelerated transvascular NO2− clearance (presumably with concomitant NO release) suggests that NO2− effects may be accentuated in such patients. These findings provide a stimulus for the clinical exploration of NO2− as a therapeutic modality in CHF.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>23472879</pmid><doi>10.1111/bph.12152</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1188 |
ispartof | British journal of pharmacology, 2013-06, Vol.169 (3), p.659-670 |
issn | 0007-1188 1476-5381 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3682712 |
source | MEDLINE; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection |
subjects | Aged Brachial Artery Cohort Studies Drug Tolerance Female Forearm heart failure Heart Failure - drug therapy Heart Failure - metabolism Heart Failure - physiopathology Hemodynamics - drug effects Humans In Vitro Techniques Infusions, Intra-Arterial Male Metabolic Clearance Rate Middle Aged Nitric Oxide - administration & dosage Nitric Oxide - analogs & derivatives Nitric Oxide - metabolism Nitric Oxide - pharmacokinetics Nitroglycerin - administration & dosage Nitroglycerin - metabolism Nitroglycerin - pharmacokinetics Nitroglycerin - pharmacology Oxidative Stress - drug effects Regional Blood Flow - drug effects Research Papers Saphenous Vein - drug effects Saphenous Vein - physiopathology sodium nitrite Sodium Nitrite - administration & dosage Sodium Nitrite - metabolism Sodium Nitrite - pharmacokinetics Sodium Nitrite - pharmacology vascular effects Vasodilation - drug effects Vasodilator Agents - administration & dosage Vasodilator Agents - metabolism Vasodilator Agents - pharmacokinetics Vasodilator Agents - pharmacology Vasomotor System - drug effects Vasomotor System - physiopathology |
title | Impact of chronic congestive heart failure on pharmacokinetics and vasomotor effects of infused nitrite |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T19%3A57%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20chronic%20congestive%20heart%20failure%20on%20pharmacokinetics%20and%20vasomotor%20effects%20of%20infused%20nitrite&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Maher,%20Abdul%20R&rft.date=2013-06&rft.volume=169&rft.issue=3&rft.spage=659&rft.epage=670&rft.pages=659-670&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.12152&rft_dat=%3Cproquest_pubme%3E3316012971%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1528624449&rft_id=info:pmid/23472879&rfr_iscdi=true |